A Phase 4 interventional study of brimonidine 0.1% (Alphagan® P) in Open-angle Glaucoma and Ocular Hypertension, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2011-11-24.
Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing brimonidine in Glaucoma, Open-Angle — 1 open to participants now, 1 under way, none of them phase 3. brimonidine · Glaucoma, Open-Angle.
Among the 18 studies testing brimonidine in Glaucoma, Open-Angle, this one is the 17th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2006, is one of 11 in phase 4, and was the 4th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →1 of the 18 studies testing brimonidine in Glaucoma, Open-Angle is open now, in 1 country. Recruiting first, the newest first:
Tulane University · Sites in United States
Ages 18+
By country, each count listing its studies:
brimonidine: first FDA approval 1996 (ALPHAGAN), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 120 across the 17 interventional studies. Of the 17 that completed or were terminated, 7 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 18 have an industry lead sponsor. The 10 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
58 studies in Glaucoma, Open-Angle by AbbVie: 1 open now, 3 under way, 1 of them phase 3. Of 54 finished, 42 (78%) have results posted.
Among the 58 studies in Glaucoma, Open-Angle by AbbVie, this one is the 34th largest by enrollment of the 34 interventional ones that give a count, is the only one that started in 2006, is one of 14 in phase 4, and was the 3rd registered.
AbbVie’s Glaucoma, Open-Angle studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing brimonidine in Glaucoma, Open-Angle, from their registry updates:
Among AbbVie’s 58 in Glaucoma, Open-Angle:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of brimonidine 0.1% three-times daily in patients with glaucoma or ocular hypertension
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
brimonidine 0.1%
Drug: brimonidine 0.1% (Alphagan® P)
Brimonidine 0.1%, 1 drop three-times daily for 4 weeks
Also known as: Alphagan® P
Intraocular Pressure (IOP) for a 24-Hour Period at Week 4
IOP for a 24-hour period separated into diurnal(7AM-11PM or awake period) and nocturnal (11PM-7AM or sleep period) at week 4. IOP is a measurement of the fluid pressure inside the eye. Measurements of IOP were taken in the sitting and supine (laying down face up) body positions during the 16-hour diurnal (awake) period and in the supine position during the 8-hour nocturnal (sleep) period.
Time frame: Week 4
Change From Baseline in Intraocular Pressure (IOP) for a 24-Hour Period at Week 4
Change from baseline in IOP for a 24-hour period separated into diurnal (7AM-11PM or awake period) and nocturnal (11PM-7AM or sleep period) at week 4. IOP is a measurement of the fluid pressure inside the eey. Measurements of IOP were taken in the sitting and supine (laying down face up) body positions during the 16-hour diurnal (awake) period and in the supine position during the 8-hour nocturnal (sleep) period. A negative number change from baseline indicates an improvement.
Time frame: Baseline, Week 4
Ocular Perfusion Pressure (OPP) for a 24-Hour Period at Week 4
Ocular perfusion pressure (OPP) calculated for a 24-hour period separated into diurnal (7AM-11PM or awake period) and nocturnal (11PM-7AM or sleep period) at week 4. Ocular perfusion pressure is blood pressure minus the intraocular pressure, which is a measurement of the fluid pressure inside the eye. Measurements of IOP and blood pressure were taken in the sitting and supine (laying down face up) body positions during the 16-hour diurnal (awake) period and in the supine position during the 8-hour nocturnal (sleep) period.
Time frame: Week 4
Change in Ocular Perfusion Pressure (OPP) Over a 24-Hour Period at Week 4
Change in ocular perfusion pressure (OPP) calculated over a 24-hour period separated into diurnal (7AM-11PM or awake period) and nocturnal (11PM-7AM or sleep period) at Week 4. Ocular perfusion pressure is blood pressure minus the intraocular pressure, which is a measurement of the fluid pressure inside the eye. Measurements of IOP and blood pressure were taken in the sitting and supine (laying down face up) body positions during the 16-hour (awake) period and in the supine position during the 8-hour nocturnal (sleep) period.
Time frame: Week 4
| Milestone | Brimonidine 0.1% |
|---|---|
| Started | 15 |
| Completed | 15 |
| Not completed | 0 |
IOP for a 24-hour period separated into diurnal(7AM-11PM or awake period) and nocturnal (11PM-7AM or sleep period) at week 4. IOP is a measurement of the fluid pressure inside the eye. Measurements of IOP were taken in the sitting and supine (laying down face up) body positions during the 16-hour diurnal (awake) period and in the supine position during the 8-hour nocturnal (sleep) period.
| Millimeters of mercury (mmHg) | Brimonidine 0.1% |
|---|---|
| Diurnal IOP Sitting at Week 4 | 16.8 ± 2.8 |
| Diurnal IOP Supine at Week 4 | 21.1 ± 2.3 |
| Nocturnal IOP Supine at Week 4 | 23.0 ± 2.8 |
Change from baseline in IOP for a 24-hour period separated into diurnal (7AM-11PM or awake period) and nocturnal (11PM-7AM or sleep period) at week 4. IOP is a measurement of the fluid pressure inside the eey. Measurements of IOP were taken in the sitting and supine (laying down face up) body positions during the 16-hour diurnal (awake) period and in the supine position during the 8-hour nocturnal (sleep) period. A negative number change from baseline indicates an improvement.
| Millimeters of mercury (mmHg) | Brimonidine 0.1% |
|---|---|
| Diurnal IOP Sitting at Baseline | 19.2 ± 2.7 |
| Diurnal IOP Supine at Baseline | 23.1 ± 2.1 |
| Nocturnal IOP Supine at Baseline | 22.7 ± 2.6 |
| Diurnal IOP Sitting Change from Baseline at Week 4 | -2.4 ± 1.4 |
| Diurnal IOP Supine Change from Baseline at Week 4 | -1.9 ± 1.3 |
| Nocturnal IOP Supine Change from Baseline at Wk 4 | 0.3 ± 1.9 |
Ocular perfusion pressure (OPP) calculated for a 24-hour period separated into diurnal (7AM-11PM or awake period) and nocturnal (11PM-7AM or sleep period) at week 4. Ocular perfusion pressure is blood pressure minus the intraocular pressure, which is a measurement of the fluid pressure inside the eye. Measurements of IOP and blood pressure were taken in the sitting and supine (laying down face up) body positions during the 16-hour diurnal (awake) period and in the supine position during the 8-hour nocturnal (sleep) period.
| Millimeters of mercury (mmHg) | Brimonidine 0.1% |
|---|---|
| Diurnal OPP Sitting at Week 4 | 46.8 ± 7.6 |
| Diurnal OPP Supine at Week 4 | 53.8 ± 9.8 |
| Nocturnal OPP Supine at Week 4 | 49.2 ± 11.2 |
Change in ocular perfusion pressure (OPP) calculated over a 24-hour period separated into diurnal (7AM-11PM or awake period) and nocturnal (11PM-7AM or sleep period) at Week 4. Ocular perfusion pressure is blood pressure minus the intraocular pressure, which is a measurement of the fluid pressure inside the eye. Measurements of IOP and blood pressure were taken in the sitting and supine (laying down face up) body positions during the 16-hour (awake) period and in the supine position during the 8-hour nocturnal (sleep) period.
| Millimeters of mercury (mmHg) | Brimonidine 0.1% |
|---|---|
| Diurnal Change in OPP Sitting at Week 4 | 1.1 ± 5.6 |
| Diurnal Change in OPP Supine at Week 4 | 0.3 ± 4.9 |
| Nocturnal Change in OPP Supine at Week 4 | -3.0 ± 6.1 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Brimonidine 0.1% | — | 0/15 (0%) | 0/15 (0%) |
| Age Continuous(years) | Brimonidine 0.1% |
|---|---|
| Mean | 58.3 ± 7.8 |
| Sex: Female, Male(Participants) | Brimonidine 0.1% |
|---|---|
| Female | 10 |
| Male | 5 |
The record gives a start of Dec 2006, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2011, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brimonidine